| 15156-3 |
Cancer Ag 125 |
ACnc |
Body fld |
Pt |
Qn |
Dilution |
|
ACTIVE |
Cancer Ag 125 [Units/volume] in Body fluid by Dilution |
|
MIN |
DefinitionDescription |
|
|
arb U/mL |
|
|
|
|
|
|
CHEM |
|
15156-3 |
|
Dilution |
|
|
Observation |
|
|
|
0 |
Cancer Ag125 Fld Dil-aCnc |
|
|
|
Y |
|
Arbitrary concentration; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; CA; CA 125; Cancer Ag125; Cancer antigen 125; Carbohydrate antigen; Carbohydrate antigen 125; Chemistry; Dil; Dilut; Fl; Fld; FLU; Fluid; Gyn; Gynecology; OB; ObGyn; Obstetrics; OC125; Point in time; QNT; Quan; Quant; Quantitative; Random; Tumor marker |
2.68 |
1.0k |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 15157-1 |
Cancer Ag 125 |
ACnc |
Ser/Plas |
Pt |
Qn |
Dilution |
|
ACTIVE |
Cancer Ag 125 [Units/volume] in Serum or Plasma by Dilution |
|
MIN |
DefinitionDescription |
|
|
arb U/mL |
|
|
|
|
|
|
CHEM |
|
15157-1 |
|
Dilution |
|
|
Observation |
|
|
|
0 |
Cancer Ag125 SerPl Dil-aCnc |
|
|
|
Y |
|
Arbitrary concentration; CA; CA 125; Cancer Ag125; Cancer antigen 125; Carbohydrate antigen; Carbohydrate antigen 125; Chemistry; Dil; Dilut; Gyn; Gynecology; OB; ObGyn; Obstetrics; OC125; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tumor marker |
2.68 |
1.0k |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 15158-9 |
Chloride |
SCnc |
Stool |
Pt |
Qn |
|
|
ACTIVE |
Chloride [Moles/volume] in Stool |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
15158-9 |
|
|
|
|
Both |
|
|
|
0 |
Chloride Stl-sCnc |
|
|
|
Y |
|
Bowel movement; Chemistry; Cl; Cl-; Faecal; Faeces; Fecal; Feces; Gastro; Gastroenterology; GI; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Stl; Stool = Fecal; Substance Concentration |
2.73 |
1.0k |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
| 15159-7 |
Coagulation factor.extrinsic pathway |
Imp |
PPP |
Pt |
Nar |
|
|
ACTIVE |
Coagulation factor extrinsic pathway [Interpretation] in Platelet poor plasma Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
15159-7 |
|
|
|
|
Observation |
|
|
|
0 |
Extrins clotting path PPP-Imp |
|
|
|
|
|
Coag; Extrins clotting path; Fac; Fact; Hematology; Heme; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Narrative; Plas; Platelet poor plasma; Point in time; Random; Report |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 1516-4 |
Glucose^2H post 100 g glucose PO |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Urine --2 hours post 100 g glucose PO |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
1516-4 |
|
|
|
|
Both |
|
|
|
0 |
Glucose 2h p 100 g Glc PO Ur-mCnc |
|
|
|
Y |
|
120 min; 120 minutes; 120min; 2 hours; 2h p 100 g Glc PO; After; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Mass concentration; p 100 g Glc PO; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
1 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 15160-5 |
Coagulation factor.intrinsic factor |
Imp |
PPP |
Pt |
Nar |
|
|
ACTIVE |
Coagulation factor Intrinsic Factor [Interpretation] in Platelet poor plasma Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
15160-5 |
|
|
|
|
Observation |
|
|
|
0 |
Coag Fact Intrinsic PPP-Imp |
|
|
|
|
|
Absorbing intrinsic; Coag; Coag Fact Intrinsic; Fac; Fact; Hematology; Heme; IF; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Narrative; Plas; Platelet poor plasma; Point in time; Random; Report |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 15161-3 |
Complement C1 esterase inhibitor.functional |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
Complement C1 esterase inhibitor.functional [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
15161-3 |
|
|
|
|
Both |
|
|
|
0 |
C1INH Functional SerPl Ql |
|
|
|
|
|
C1 inactivator; C1 inhibiting factor; C1INA; C1INH; C1-INH; C1INH Functional; Comp; Complmt; HEMATOLOGY/CELL COUNTS; Inhib; Inhibit; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 15162-1 |
Complement C1q |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Complement C1q [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
HEM/BC |
|
15162-1 |
|
|
|
|
Both |
|
|
|
0 |
C1q Fld-mCnc |
|
|
|
Y |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Comp; Complement c1q binding; Complmt; Fl; Fld; FLU; Fluid; HEMATOLOGY/CELL COUNTS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.44 |
1.0k |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 15163-9 |
Complement C2 |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Complement C2 [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
HEM/BC |
|
15163-9 |
|
|
|
|
Both |
|
|
|
0 |
C2 Fld-mCnc |
|
|
|
Y |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Comp; Complmt; Fl; Fld; FLU; Fluid; HEMATOLOGY/CELL COUNTS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.44 |
1.0k |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 15164-7 |
Complement C3 |
MCnc |
Synv fld |
Pt |
Qn |
|
|
ACTIVE |
Complement C3 [Mass/volume] in Synovial fluid |
|
MIN |
DefinitionDescription |
|
|
g/L |
|
|
|
|
|
|
HEM/BC |
|
15164-7 |
|
|
|
|
Both |
|
|
|
0 |
C3 Snv-mCnc |
|
|
|
Y |
|
Beta 1 C-globulin; Comp; Complmt; HEMATOLOGY/CELL COUNTS; Joint aspirate; Joint fld; Joint flu; Joint fluid; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; SF; SNV; Syn; Syn fl; Synov; Synovial fluid |
2.73 |
1.0k |
|
|
|
|
|
|
|
g/L |
|
|
|
0 |
| 15165-4 |
Complement C4 |
MCnc |
Synv fld |
Pt |
Qn |
|
|
ACTIVE |
Complement C4 [Mass/volume] in Synovial fluid |
|
MIN |
DefinitionDescription |
|
|
g/L |
|
|
|
|
|
|
HEM/BC |
|
15165-4 |
|
|
|
|
Both |
|
|
|
0 |
C4 Snv-mCnc |
|
|
|
Y |
|
Beta 1 E-globulin; Comp; Complmt; HEMATOLOGY/CELL COUNTS; Joint aspirate; Joint fld; Joint flu; Joint fluid; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; SF; SNV; Syn; Syn fl; Synov; Synovial fluid |
2.73 |
1.0k |
|
|
|
|
|
|
|
g/L |
|
|
|
0 |
| 15166-2 |
Complement C5 |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Complement C5 [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
HEM/BC |
|
15166-2 |
|
|
|
|
Both |
|
|
|
0 |
C5 Fld-mCnc |
|
|
|
Y |
|
B/F; Beta 1 F-globulin; BF; bod; Bodies; Body fluid; Body fluid, unsp; Comp; Complmt; Fl; Fld; FLU; Fluid; HEMATOLOGY/CELL COUNTS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.44 |
1.0k |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 15167-0 |
Complement C6 |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Complement C6 [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
HEM/BC |
|
15167-0 |
|
|
|
|
Both |
|
|
|
0 |
C6 Fld-mCnc |
|
|
|
Y |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Comp; Complmt; Fl; Fld; FLU; Fluid; HEMATOLOGY/CELL COUNTS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.44 |
1.0k |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 15168-8 |
Complement total hemolytic C50 |
ACnc |
Body fld |
Pt |
Qn |
IA |
|
ACTIVE |
Complement total hemolytic C50 [Units/volume] in Body fluid by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
15168-8 |
|
IA |
|
|
Both |
|
|
|
0 |
Comp C50 Fld IA-aCnc |
|
|
|
Y |
|
Arbitrary concentration; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Comp; Comp C50; Complmt; EIA; ELFA; ELISA; Enzyme immunoassay; Fl; Fld; FLU; Fluid; HEMATOLOGY/CELL COUNTS; IAA; MEIA; Point in time; QNT; Quan; Quant; Quantitative; Random; SUDS; Tot; Total Hem Comp; Totl |
2.69 |
1.0k |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 15169-6 |
Complement total hemolytic C50 |
ACnc |
Ser/Plas |
Pt |
Qn |
IA |
|
ACTIVE |
Complement total hemolytic C50 [Units/volume] in Serum or Plasma by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
15169-6 |
|
IA |
|
|
Both |
|
|
|
0 |
Comp C50 SerPl IA-aCnc |
|
|
|
Y |
|
Arbitrary concentration; Comp; Comp C50; Complmt; EIA; ELFA; ELISA; Enzyme immunoassay; HEMATOLOGY/CELL COUNTS; IAA; MEIA; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; SUDS; Tot; Total Hem Comp; Totl |
2.73 |
1.0k |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 1517-2 |
Glucose^2H post 50 g lactose PO |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Serum or Plasma --2 hours post 50 g lactose PO |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
1517-2 |
|
|
|
|
Both |
|
|
|
0 |
Glucose 2h p 50 g Lac PO SerPl-mCnc |
|
|
|
Y |
|
120 min; 120 minutes; 120min; 2 hours; 2h p 50 g Lac PO; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; LTT; Mass concentration; p 50 g Lact PO; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 15170-4 |
Complement total hemolytic C50 |
ACnc |
Synv fld |
Pt |
Qn |
IA |
|
ACTIVE |
Complement total hemolytic C50 [Units/volume] in Synovial fluid by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
15170-4 |
|
IA |
|
|
Both |
|
|
|
0 |
Comp C50 Snv IA-aCnc |
|
|
|
Y |
|
Arbitrary concentration; Comp; Comp C50; Complmt; EIA; ELFA; ELISA; Enzyme immunoassay; HEMATOLOGY/CELL COUNTS; IAA; Joint aspirate; Joint fld; Joint flu; Joint fluid; MEIA; Point in time; QNT; Quan; Quant; Quantitative; Random; SF; SNV; SUDS; Syn; Syn fl; Synov; Synovial fluid; Tot; Total Hem Comp; Totl |
2.69 |
1.0k |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 15171-2 |
Cryoglobulin.IgA |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Cryoglobulin.IgA [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
arb U/mL |
|
|
|
|
|
|
SERO |
|
15171-2 |
|
|
|
|
Both |
|
|
|
0 |
Cryoglob IgA Ser-aCnc |
|
|
|
Y |
|
Arbitrary concentration; Cryo; Cryoglob IgA; Cryoglobulins; Cryoprecipitate; Immune globulin A; Immunoglobulin A; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; Serum; SR |
2.73 |
1.0k |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
Corrected Example and UCUM Units. |
0 |
| 15172-0 |
Cryoglobulin.IgG |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Cryoglobulin.IgG [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
arb U/mL |
|
|
|
|
|
|
SERO |
|
15172-0 |
|
|
|
|
Both |
|
|
|
0 |
Cryoglob IgG Ser-aCnc |
|
|
|
Y |
|
Arbitrary concentration; Cryo; Cryoglob IgG; Cryoglobulins; Cryoprecipitate; Immune globulin G; Immunoglobulin G; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; Serum; SR |
2.73 |
1.0k |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
Corrected Example and UCUM Units. |
0 |
| 15173-8 |
Cryoglobulin.IgM |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Cryoglobulin.IgM [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
arb U/mL |
|
|
|
|
|
|
SERO |
|
15173-8 |
|
|
|
|
Both |
|
|
|
0 |
Cryoglob IgM Ser-aCnc |
|
|
|
Y |
|
Arbitrary concentration; Cryo; Cryoglob IgM; Cryoglobulins; Cryoprecipitate; Immune globulin M; Immunoglobulin M; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; Serum; SR |
2.73 |
1.0k |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
Corrected Example and UCUM Units. |
0 |
| 15174-6 |
Cryoglobulin/Serum.total |
VFr |
Ser |
Pt |
Qn |
Spun Westergren tube |
|
ACTIVE |
Cryocrit of Serum by Spun Westergren |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CHEM |
|
15174-6 |
|
Spun Westergren tube |
|
|
Both |
|
|
|
0 |
Cryocrit Ser Spun Westergren |
|
|
|
Y |
|
Centrifugation; Centrifuged; Chemistry; Cryo; Cryoglobulins; Cryoprecipitate; Percent; Point in time; Post centrifugation; QNT; Quan; Quant; Quantitative; Random; Ser; Serum; SR; Tot; Totl; Volfr; Volume fraction; Westerg; Westrgrn |
2.73 |
1.0k |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 15175-3 |
Cryoproteins |
Imp |
Ser/Plas |
Pt |
Nom |
Electrophoresis.agarose gel |
|
ACTIVE |
Cryoproteins [Interpretation] in Serum or Plasma by Electrophoresis agarose gel |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
15175-3 |
|
Electrophoresis.agarose gel |
|
|
Observation |
|
|
|
0 |
Cryoproteins SerPl AG Elph-Imp |
|
|
|
|
|
AG Elph; Chemistry; Cryoprotein; Elec; Elect; Electr; Electro; Electrophhrs; Electrophrs; Elp; Elph; Ep; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; Pl; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0k |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 15176-1 |
Cryoproteins |
Prid |
Ser/Plas |
Pt |
Nom |
|
|
ACTIVE |
Cryoproteins identified in Serum or Plasma |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
15176-1 |
|
|
|
|
Both |
|
|
|
0 |
Cryoproteins SerPl |
|
|
|
|
|
Chemistry; Cryoprotein; Identity or presence; Nominal; Pl; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.79 |
1.0k |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
| 15177-9 |
DNA double strand Ab |
ACnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
DNA double strand Ab [Units/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
IU/mL |
|
|
|
|
|
|
SERO |
|
15177-9 |
|
|
|
|
Both |
|
|
|
0 |
dsDNA Ab Fld-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Deoxyribonucleic acid; DNA binding ab; ds; dsDNA; dsnda; Fl; Fld; FLU; Fluid; Native DNA; N-DNA; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; Stranded; Strnd |
2.42 |
1.0k |
|
|
|
|
|
|
|
[IU]/mL |
|
|
|
0 |
| 15178-7 |
Complement factor B |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Complement factor B [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
15178-7 |
|
|
|
|
Both |
|
|
|
0 |
Comp Fact B Fld-mCnc |
|
|
|
Y |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; C3 proactivator; C3-5 Converting Enzyme; C3PA; Comp; Comp Fact B; Complement c3 proactivator+activator; Complement Protein B; Complmt; CVFBb; Fac; Fact; Factor B; Fl; Fld; FLU; Fluid; Glycine rich beta glycoprotein; Heat labile factor; HEMATOLOGY/CELL COUNTS; Level; Mass concentration; Point in time; Properdin Factor B; QNT; Quan; Quant; Quantitative; Random |
2.34 |
1.0k |
|
|
|
|
|
|
|
|
|
|
|
0 |
